Regulators of NFAT and/or store-operated calcium entry
Embodiments of the inventions relates to modulating NFAT activity, modulating store-operated Ca 2+ entry into a cell and treating and/or preventing hyperactivity or inappropriate immune response by inhibiting the expression or activities of proteins involved in the calcineurin/NFAT axis.
1. A method of modulating NFAT activity in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity of a UEV3 protein and/or the expression of UEV3 gene.
2. The method of claim 1 , wherein the subject is suffering from a cell proliferation disease or disorder.
3. The method of claim 2 , wherein the cell proliferation disease or disorder is a neoplastic cell proliferation disorder.
4. The method of claim 2 , wherein the neoplastic cell proliferation disorder is a therapy resistant cancer, a metastasis or malignant cancer.
5. The method of claim 1 , wherein the subject is suffering from a cardiovascular disorder.
6. The method of claim 5 , wherein the cardiovascular disorder is cardiac hypertrophy, restenosis, atherosclerosis, or angiogenesis.
7. The method of claim 1 , wherein the subject is suffering from a bone disease associated with excessive osteoclast formation and the excessive activity needs to be suppressed.
8. The method of claim 1 , wherein the subject is suffering from an angiogenic disease or disorder.
9. The method of claim 8 , wherein the angiogenesis disorder is associated with VEGF-induced and IL-1 induced gene expression.
10. The method of claim 8 , wherein the angiogenesis disorder is selected from a group consisting of cancer, age-related macular degeneration, diabetic retinopathy; rheumatoid arthritis; Alzheimer's disease; obesity and endometriosis.
11. The method of claim 1 , wherein the agent is nucleic acid inhibitor which inhibits gene expression.
12. The method of claim 11 , wherein the nucleic acid inhibitor is an siRNA or shRNA.
13. A method of modulating store-operated Ca 2+ entry into a cell, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity of a UEV3 protein and/or the expression of UEV3.
14. The method of claim 13 , wherein the agent is a nucleic acid inhibitor which inhibits gene expression.
15. A method of treating and/or preventing hyperactivity or inappropriate immune response in a subject in need thereof, the method comprising administering a therapeutically effective amount of a pharmaceutical composition comprising an agent that inhibits the activity of a UEV3 protein and/or the expression of UEV3 gene.
16. The method of claim 15 , wherein the hyperactivity or inappropriate immune response in a subject is associated with acute and chronic immune diseases selected from a group consisting of asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, rheumatoid arthritis, insulin-dependent diabetes, inflammatory bowel disease, autoimmune thyroiditis, hemolytic anemia, multiple sclerosis, transplant graft rejections and graft-versus-host disease.
17. The method of claim 15 , wherein the agent is a nucleic acid inhibitor which inhibits gene expression.
18. The method of claim 17 , wherein the nucleic acid inhibitor is an siRNA or shRNA.